

Manuel Comabella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3532069/publications.pdf>

Version: 2024-02-01

238
papers

16,009
citations

26567

56
h-index

19136

118
g-index

248
all docs

248
docs citations

248
times ranked

19115
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011, 476, 214-219.	13.7	2,400
2	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 577-589.	4.9	1,177
3	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019, 365, .	6.0	710
4	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Neurology</i> , 2009, 73, 1914-1922.	1.5	653
5	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015, 138, 1863-1874.	3.7	403
6	Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. <i>Neurology</i> , 2008, 70, 1079-1083.	1.5	317
7	Defining the response to interferon- β in relapsing-remitting multiple sclerosis patients. <i>Annals of Neurology</i> , 2006, 59, 344-352.	2.8	295
8	Baseline MRI predicts future attacks and disability in clinically isolated syndromes. <i>Neurology</i> , 2006, 67, 968-972.	1.5	253
9	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	1.4	249
10	Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. <i>Brain</i> , 2010, 133, 1082-1093.	3.7	240
11	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1005-1015.	0.9	228
12	Measures in the first year of therapy predict the response to interferon β in MS. <i>Multiple Sclerosis Journal</i> , 2009, 15, 848-853.	1.4	215
13	Body fluid biomarkers in multiple sclerosis. <i>Lancet Neurology</i> , The, 2014, 13, 113-126.	4.9	204
14	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
15	Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.. <i>Journal of Clinical Investigation</i> , 1998, 102, 671-678.	3.9	197
16	A type I interferon signature in monocytes is associated with poor response to interferon- β in multiple sclerosis. <i>Brain</i> , 2009, 132, 3353-3365.	3.7	186
17	Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. <i>Annals of Neurology</i> , 2010, 67, 159-169.	2.8	181
18	Plasma osteopontin levels in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 158, 231-239.	1.1	171

#	ARTICLE	IF	CITATIONS
19	Brainstem lesions in clinically isolated syndromes. <i>Neurology</i> , 2010, 75, 1933-1938.	1.5	164
20	Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls. <i>American Journal of Human Genetics</i> , 2013, 92, 854-865.	2.6	164
21	Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 337-44.	4.9	154
22	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015, 138, 918-931.	3.7	147
23	Transcription-Based Prediction of Response to IFN β Using Supervised Computational Methods. <i>PLoS Biology</i> , 2004, 3, e2.	2.6	144
24	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. <i>Nature Medicine</i> , 2014, 20, 272-282.	15.2	141
25	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1802-1809.	1.4	133
26	Immunopathogenesis of multiple sclerosis. <i>Clinical Immunology</i> , 2012, 142, 2-8.	1.4	128
27	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	3.7	115
28	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018, 175, 1679-1687.e7.	13.5	115
29	Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β : Implications for clinical trials. <i>Annals of Neurology</i> , 2002, 52, 400-406.	2.8	114
30	Predicting responders to therapies for multiple sclerosis. <i>Nature Reviews Neurology</i> , 2009, 5, 553-560.	4.9	114
31	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021, 28, 3384-3395.	1.7	111
32	Tumor necrosis factor alpha (TNF- α), anti-TNF- α and demyelination revisited: An ongoing story. <i>Journal of Neuroimmunology</i> , 2011, 234, 1-6.	1.1	109
33	Is optic neuritis more benign than other first attacks in multiple sclerosis?. <i>Annals of Neurology</i> , 2005, 57, 210-215.	2.8	108
34	Relationship between MRI lesion activity and response to IFN- β in relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2008, 14, 479-484.	1.4	104
35	Genome-wide Scan of 500,000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 972-8.	4.9	104
36	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603.	1.4	101

#	ARTICLE	IF	CITATIONS
37	Serum neurofilament light as a biomarker in progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, 436-444.	1.5	100
38	Identification of a Novel Risk Locus for Multiple Sclerosis at 13q31.3 by a Pooled Genome-Wide Scan of 500,000 Single Nucleotide Polymorphisms. <i>PLoS ONE</i> , 2008, 3, e3490.	1.1	99
39	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. <i>Brain</i> , 2018, 141, 1075-1084.	3.7	98
40	Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. <i>Brain</i> , 2011, 134, 693-703.	3.7	96
41	NLRP3 inflammasome is associated with the response to IFN- γ in patients with multiple sclerosis. <i>Brain</i> , 2015, 138, 644-652.	3.7	93
42	NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. <i>Brain</i> , 2020, 143, 1414-1430.	3.7	92
43	Metabolomic signatures associated with disease severity in multiple sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2017, 4, e321.	3.1	89
44	Biomarkers in Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a029058.	2.9	88
45	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	0.6	86
46	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016, 87, 1076-1084.	1.5	85
47	Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis. <i>Biomarkers in Medicine</i> , 2014, 8, 653-661.	0.6	84
48	The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. <i>Genes and Immunity</i> , 2010, 11, 439-445.	2.2	79
49	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , 2018, 24, 301-312.	1.4	79
50	Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. <i>Clinical Immunology</i> , 2011, 141, 348-356.	1.4	72
51	Genomics in multiple sclerosis—Current state and future directions. <i>Journal of Neuroimmunology</i> , 2007, 187, 1-8.	1.1	66
52	Multiple sclerosis: current treatment algorithms. <i>Current Opinion in Neurology</i> , 2011, 24, 230-237.	1.8	65
53	PML risk stratification using anti-JCV antibody index and L-selectin. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1048-1060.	1.4	62
54	Targeting dendritic cells to treat multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010, 6, 499-507.	4.9	61

#	ARTICLE	IF	CITATIONS
55	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. <i>Brain</i> , 2013, 136, 1778-1782.	3.7	60
56	Disability progression markers over 6â€“12â€“years in interferon-Î²-treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 322-330.	1.4	60
57	Identification of a functional variant in the <i>KIF5A-CYP27B1-METTL1-FAM119B</i> locus associated with multiple sclerosis. <i>Journal of Medical Genetics</i> , 2013, 50, 25-33.	1.5	59
58	A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. <i>Genes and Immunity</i> , 2012, 13, 21-28.	2.2	56
59	Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. <i>European Journal of Neurology</i> , 2012, 19, 899-904.	1.7	55
60	Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?. <i>Multiple Sclerosis Journal</i> , 2010, 16, 55-61.	1.4	54
61	Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 983-990.	1.4	54
62	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643.	3.7	54
63	Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. <i>European Journal of Neurology</i> , 2018, 25, 1189-1191.	1.7	53
64	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. <i>Multiple Sclerosis International</i> , 2011, 2011, 1-9.	0.4	52
65	N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 2338-2343.	1.8	52
66	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 912-923.	1.4	52
67	Transcriptomics: mRNA and alternative splicing. <i>Journal of Neuroimmunology</i> , 2012, 248, 23-31.	1.1	51
68	Immunoglobulin <i>κ</i> oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , 2014, 76, 231-240.	2.8	51
69	Precision medicine in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016, 29, 254-262.	1.8	51
70	Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. <i>Multiple Sclerosis Journal</i> , 2003, 9, 39-43.	1.4	49
71	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2019, 92, e1507-e1516.	1.5	49
72	Neutralising antibodies to interferon Î² in multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 827-837.	1.8	48

#	ARTICLE	IF	CITATIONS
73	Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015, 77, 447-457.	2.8	48
74	Interferon- β treatment alters peripheral blood monocytes chemokine production in MS patients. <i>Journal of Neuroimmunology</i> , 2002, 126, 205-212.	1.1	46
75	Targeting Inflammasomes to Treat Neurological Diseases. <i>Annals of Neurology</i> , 2021, 90, 177-188.	2.8	46
76	Search for Specific Biomarkers of IFN β Bioactivity in Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e23634.	1.1	45
77	Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 1421.	4.9	44
78	ANKRD55 and DHCR7 are novel multiple sclerosis risk loci. <i>Genes and Immunity</i> , 2012, 13, 253-257.	2.2	44
79	Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 484-491.	2.0	43
80	A functional variant that affects exon-skipping and protein expression of <i>SP140</i> as genetic mechanism predisposing to multiple sclerosis. <i>Human Molecular Genetics</i> , 2015, 24, 5619-5627.	1.4	43
81	Significant clinical worsening after natalizumab withdrawal: Predictive factors. <i>Multiple Sclerosis Journal</i> , 2015, 21, 780-785.	1.4	43
82	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016, 87, 1368-1374.	1.5	42
83	Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. <i>Clinical Immunology</i> , 2009, 130, 145-150.	1.4	41
84	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1658-1669.	1.4	41
85	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. <i>Multiple Sclerosis Journal</i> , 2014, 20, 577-587.	1.4	40
86	Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 67-84.	1.0	39
87	SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 524-531.	1.4	38
88	Altered maturation of circulating dendritic cells in primary progressive MS patients. <i>Journal of Neuroimmunology</i> , 2006, 175, 183-191.	1.1	37
89	Role of tumour necrosis factor (TNF)- α and <i>TNFRSF1A</i> R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2011, 166, 338-345.	1.1	36
90	Replication of top markers of a genome-wide association study in multiple sclerosis in Spain. <i>Genes and Immunity</i> , 2011, 12, 110-115.	2.2	36

#	ARTICLE	IF	CITATIONS
91	Evaluating the response to glatiramer acetate in relapsingâ€“remitting multiple sclerosis (RRMS) patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1602-1608.	1.4	36
92	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016, 134, 281-294.	2.1	36
93	A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease. <i>Journal of Neuroimmunology</i> , 2003, 143, 124-128.	1.1	35
94	Implication of the tollâ€“like receptor 4 pathway in the response to interferonâ€“Î² in multiple sclerosis. <i>Annals of Neurology</i> , 2011, 70, 634-645.	2.8	35
95	Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2012, 9, 139.	3.1	35
96	Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	35
97	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021, 97, e1641-e1652.	1.5	35
98	Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonâ€“Î² therapy in multiple sclerosis. <i>Genes and Immunity</i> , 2011, 12, 466-472.	2.2	34
99	Genome-wide significant association of ANKRD5rs6859219 and multiple sclerosis risk. <i>Journal of Medical Genetics</i> , 2013, 50, 140-143.	1.5	34
100	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015, 52, 848-855.	1.5	34
101	Cytokine profiles show heterogeneity of interferonâ€“Î² response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e202.	3.1	34
102	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017, 12, e0170395.	1.1	34
103	HLA class I and II alleles and response to treatment with interferon-beta in relapsingâ€“remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009, 210, 116-119.	1.1	33
104	Pharmacogenomics in neurology: Current state and future steps. <i>Annals of Neurology</i> , 2011, 70, 684-697.	2.8	33
105	DNA-based vaccines for multiple sclerosis: Current status and future directions. <i>Clinical Immunology</i> , 2012, 142, 76-83.	1.4	32
106	Roles of the ubiquitin peptidase <i>USP18</i> in multiple sclerosis and the response to interferonâ€“Î² treatment. <i>European Journal of Neurology</i> , 2013, 20, 1390-1397.	1.7	32
107	Optic Nerve Topography in Multiple Sclerosis Diagnosis. <i>Neurology</i> , 2021, 96, e482-e490.	1.5	32
108	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. <i>Human Molecular Genetics</i> , 2016, 25, 308-316.	1.4	31

#	ARTICLE	IF	CITATIONS
109	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	3.9	31
110	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , 2014, 83, 1210-1216.	1.5	30
111	Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. <i>CNS Drugs</i> , 2016, 30, 41-51.	2.7	29
112	Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes. <i>Multiple Sclerosis Journal</i> , 2012, 18, 959-965.	1.4	28
113	<i>TNFRSF1A</i> polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. <i>Neurology</i> , 2013, 80, 2010-2016.	1.5	28
114	Ancient and Recent Selective Pressures Shaped Genetic Diversity at AIM2-Like Nucleic Acid Sensors. <i>Genome Biology and Evolution</i> , 2014, 6, 830-845.	1.1	28
115	Validation of semaphorin 7A and ala ¹² -his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2014, 11, 181.	3.1	28
116	Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 318-328.	2.5	28
117	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2017, 17, 312-318.	0.9	28
118	Plasma chitotriosidase activity in multiple sclerosis. <i>Clinical Immunology</i> , 2009, 131, 216-222.	1.4	27
119	Gender-Associated Differences of Perforin Polymorphisms in the Susceptibility to Multiple Sclerosis. <i>Journal of Immunology</i> , 2010, 185, 5392-5404.	0.4	27
120	Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta. <i>PLoS ONE</i> , 2013, 8, e60994.	1.1	27
121	Lesion topographies in multiple sclerosis diagnosis. <i>Neurology</i> , 2017, 89, 2351-2356.	1.5	27
122	Chitinase 3-like 1 is neurotoxic in primary cultured neurons. <i>Scientific Reports</i> , 2020, 10, 7118.	1.6	27
123	Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 164, 140-147.	1.1	26
124	Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 48.	3.1	26
125	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. <i>Journal of Neuroinflammation</i> , 2018, 15, 265.	3.1	25
126	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. <i>Neuron</i> , 2016, 92, 333-335.	3.8	24

#	ARTICLE	IF	CITATIONS
127	Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. <i>Journal of Neurology</i> , 2008, 255, 1136-1141.	1.8	23
128	Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment. <i>PLoS ONE</i> , 2013, 8, e82796.	1.1	23
129	The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1329-1339.	1.4	23
130	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019, 326, 19-27.	1.1	22
131	Novel Insights into the Multiple Sclerosis Risk Gene <i>ANKRD55</i> . <i>Journal of Immunology</i> , 2016, 196, 4553-4565.	0.4	21
132	Decreased MMP-9 production in primary progressive multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2004, 10, 376-380.	1.4	20
133	Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009, 213, 142-147.	1.1	20
134	Orchestrating innate immune responses in multiple sclerosis: Molecular players. <i>Journal of Neuroimmunology</i> , 2010, 225, 5-12.	1.1	20
135	IFN- γ pharmacogenomics in multiple sclerosis. <i>Pharmacogenomics</i> , 2010, 11, 1137-1148.	0.6	20
136	EBV-specific immune responses in patients with multiple sclerosis responding to IFN- γ therapy. <i>Multiple Sclerosis Journal</i> , 2012, 18, 605-609.	1.4	20
137	Concise Review: Modeling Multiple Sclerosis With Stem Cell Biological Platforms: Toward Functional Validation of Cellular and Molecular Phenotypes in Inflammation-Induced Neurodegeneration. <i>Stem Cells Translational Medicine</i> , 2015, 4, 252-260.	1.6	20
138	The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?. <i>Multiple Sclerosis Journal</i> , 2016, 22, 18-33.	1.4	20
139	Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1362-1371.	1.7	20
140	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. <i>Multiple Sclerosis Journal</i> , 2021, 27, 913-921.	1.4	20
141	Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. <i>Journal of Neurology</i> , 2010, 257, 742-746.	1.8	19
142	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1193-1196.	1.4	19
143	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon- γ therapy in multiple sclerosis. <i>Journal of Medical Genetics</i> , 2014, 51, 395-400.	1.5	19
144	Pharmacogenomic study in patients with multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e154.	3.1	19

#	ARTICLE	IF	CITATIONS
145	CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	19
146	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011, 239, 101-104.	1.1	18
147	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2016, 87, 2491-2494.	1.5	18
148	TNF- α converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 701-706.	1.8	17
149	Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. <i>Autoimmunity</i> , 2014, 47, 127-133.	1.2	17
150	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, e1143.	3.1	17
151	Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS. <i>Clinical Immunology</i> , 2009, 133, 364-374.	1.4	16
152	Value of NMO-IgG determination at the time of presentation as CIS. <i>Neurology</i> , 2012, 78, 1608-1611.	1.5	16
153	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 303, 62-65.	1.1	16
154	Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006, 180, 147-158.	1.1	15
155	Antiviral immune response in patients with multiple sclerosis and healthy siblings. <i>Multiple Sclerosis Journal</i> , 2010, 16, 355-358.	1.4	15
156	Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis. <i>Journal of Neuroimmunology</i> , 2015, 278, 277-279.	1.1	15
157	Simultaneous CMV and <i>Listeria</i> infection following alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2019, 92, 296-298.	1.5	15
158	CSF Chitinase 3 Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	15
159	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017, 82, 186-195.	2.8	14
160	Immunomodulatory Effects Associated with Cladribine Treatment. <i>Cells</i> , 2021, 10, 3488.	1.8	14
161	Single-Nucleotide Polymorphisms in Response to Interferon-Beta Therapy in Multiple Sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 727-732.	0.5	13
162	Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013, 263, 152-154.	1.1	13

#	ARTICLE	IF	CITATIONS
163	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. <i>G3: Genes, Genomes, Genetics</i> , 2016, 6, 2073-2079.	0.8	13
164	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 685139.	2.2	13
165	Genetic association of CASP8 polymorphisms with primary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010, 222, 70-75.	1.1	12
166	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. <i>Journal of Neuroimmunology</i> , 2015, 288, 98-101.	1.1	12
167	Decreased soluble IFN- γ receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. <i>Multiple Sclerosis Journal</i> , 2017, 23, 937-945.	1.4	12
168	Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. <i>Epigenomics</i> , 2020, 12, 2065-2076.	1.0	12
169	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	12
170	United Europeans for development of pharmacogenomics in multiple sclerosis network. <i>Pharmacogenomics</i> , 2009, 10, 885-894.	0.6	11
171	Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2014, 1, e47.	3.1	11
172	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1507-1510.	1.4	11
173	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1138-1145.	1.4	11
174	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1802-1810.	1.4	10
175	Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation. <i>Journal of Neuroimmunology</i> , 2015, 289, 12-20.	1.1	10
176	Interferon-beta affects mitochondrial activity in CD4 ⁺ lymphocytes: Implications for mechanism of action in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1262-1270.	1.4	10
177	Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis. <i>Scientific Reports</i> , 2017, 7, 13544.	1.6	10
178	Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines. <i>Stem Cell Research</i> , 2017, 24, 155-159.	0.3	10
179	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2022, 28, 71-81.	1.4	10
180	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 452-459.	1.8	10

#	ARTICLE	IF	CITATIONS
181	Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2004, 10, 618-620.	1.4	9
182	Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 245, 98-101.	1.1	9
183	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020, 11, 579438.	1.1	9
184	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2014, 272, 51-55.	1.1	8
185	Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene. <i>American Journal of Pathology</i> , 2014, 184, 2420-2429.	1.9	8
186	Cell-specific effects in different immune subsets associated with <i>SOCS1</i> genotypes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1498-1512.	1.4	8
187	Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 732-740.	0.9	8
188	Plasma levels of 15dâ€PGJ ₂ are not altered in multiple sclerosis. <i>European Journal of Neurology</i> , 2009, 16, 1197-1201.	1.7	7
189	Short commentary on "a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking". <i>Multiple Sclerosis Journal</i> , 2010, 16, 129-132.	1.4	7
190	Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 271, 56-59.	1.1	7
191	Are Leber's mitochondrial DNA mutations associated with aquaporin-4 autoimmunity?. <i>Multiple Sclerosis Journal</i> , 2016, 22, 393-394.	1.4	7
192	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2018, 15, 296.	3.1	7
193	Modelling multiple sclerosis using induced pluripotent stem cells. <i>Journal of Neuroimmunology</i> , 2020, 349, 577425.	1.1	7
194	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 950-957.	1.4	7
195	Association Cluster Detector: a tool for heuristic detection of significance clusters in whole-genome scans. <i>Bioinformatics</i> , 2005, 21, ii180-ii181.	1.8	6
196	Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort. <i>Multiple Sclerosis Journal</i> , 2007, 13, 731-736.	1.4	6
197	Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 412-414.	1.4	6
198	Decision tree based fuzzy classifier of magnetic resonance spectra from cerebrospinal fluid samples. <i>Fuzzy Sets and Systems</i> , 2011, 170, 43-63.	1.6	6

#	ARTICLE	IF	CITATIONS
199	Breast regression protein-39 is not required for experimental autoimmune encephalomyelitis induction. <i>Clinical Immunology</i> , 2015, 160, 133-141.	1.4	6
200	Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled "MS arising during Tocilizumab therapy for rheumatoid arthritis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 257-258.	1.4	6
201	Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55-IL6ST Gene Region in Immature Dendritic Cells. <i>Frontiers in Immunology</i> , 2021, 12, 816930.	2.2	6
202	An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. <i>Revista De Neurologia</i> , 2011, 52, 321-30.	7.6	6
203	B cell expression of the inhibitory Fc γ 3 receptor is unchanged in early MS. <i>Journal of Neuroimmunology</i> , 2010, 223, 135-137.	1.1	5
204	Epstein-Barr virus and multiple sclerosis: causation or association?. <i>Future Microbiology</i> , 2010, 5, 1617-1619.	1.0	5
205	TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2013, 261, 146-148.	1.1	5
206	Cellular immune responses in multiple sclerosis patients treated with interferon-beta. <i>Clinical and Experimental Immunology</i> , 2013, 171, 243-246.	1.1	5
207	Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0134414.	1.1	5
208	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1535-1538.	1.4	5
209	A pharmacogenetic study implicates NINJ2 in the response to Interferon- γ in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1074-1082.	1.4	5
210	A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells. <i>Journal of Clinical Medicine</i> , 2020, 9, 625.	1.0	5
211	Angiogenin in the Neurogenic Subventricular Zone After Stroke. <i>Frontiers in Neurology</i> , 2021, 12, 662235.	1.1	5
212	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. <i>Journal of Neurology</i> , 2022, 269, 1764-1772.	1.8	5
213	Late-onset metachromatic leukodystrophy clinically presenting as isolated peripheral neuropathy: compound heterozygosity for the IVS2+1G->A mutation and a newly identified missense mutation (Thr408Ile) in a Spanish family. <i>Annals of Neurology</i> , 2001, 50, 108-12.	2.8	5
214	A Polymorphism Within the MBP Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 771.	2.2	4
215	Identification of the genetic mechanism that associates <i>L3MBTL3</i> to multiple sclerosis. <i>Human Molecular Genetics</i> , 2022, 31, 2155-2163.	1.4	4
216	Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non-autonomous neuronal damage. <i>Clinical and Translational Medicine</i> , 2022, 12, e837.	1.7	4

#	ARTICLE	IF	CITATIONS
217	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. <i>Laboratoriums Medizin</i> , 2010, 34, 1-12.	0.1	3
218	New technologies for biomarker discovery in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 248, 1.	1.1	3
219	Increased expression of dedicator-cytokines-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016, 1, .	1.1	3
220	Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852098014.	1.4	3
221	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. <i>Frontiers in Immunology</i> , 2021, 12, 760546.	2.2	3
222	Multiple sclerosis: Immunopathological heterogeneity and its implications. <i>European Journal of Immunology</i> , 2022, 52, 869-881.	1.6	3
223	DNA Vaccination Techniques. <i>Methods in Molecular Biology</i> , 2014, 1304, 39-50.	0.4	2
224	A case of neuromyelitis optica harboring both anti-aquaporin-4 antibodies and a pathogenic mitochondrial DNA mutation for Leber's hereditary optic neuropathy: clinical commentary. <i>Multiple Sclerosis Journal</i> , 2014, 20, 261-261.	1.4	2
225	No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 271, 49-52.	1.1	2
226	B cells and variant BAFF in autoimmune disease. <i>Nature Reviews Neurology</i> , 2017, 13, 453-454.	4.9	2
227	Pharmacogenomics in multiple sclerosis: getting the right medicine to the right patient. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 623-629.	0.2	1
228	Therapeutic strategies in multiple sclerosis. <i>Clinical Immunology</i> , 2012, 142, 1.	1.4	1
229	Treatment with interferon-beta does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2013, 255, 102-104.	1.1	1
230	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. <i>Human Mutation</i> , 2020, 41, 1308-1320.	1.1	1
231	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. <i>Cells</i> , 2020, 9, 175.	1.8	1
232	Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, e1065.	3.1	1
233	Corrigendum to "HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis" [J. Neuroimmunol. 210(2009)116-119]. <i>Journal of Neuroimmunology</i> , 2009, 214, 132.	1.1	0
234	Reply: Plasma chitotriosidase activity in multiple sclerosis. <i>Clinical Immunology</i> , 2009, 133, 284.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Re: CASP8 in MS. Journal of Neuroimmunology, 2011, 230, 193-193.	1.1	0
236	Risk of multiple sclerosis in children with acute demyelination. Lancet Neurology, The, 2011, 10, 399-400.	4.9	0
237	Correction: Gender-Associated Differences of Perforin Polymorphisms in the Susceptibility to Multiple Sclerosis. Journal of Immunology, 2011, 187, 1518-1521.	0.4	0
238	Reply. Annals of Neurology, 2017, 82, 647-648.	2.8	0